The September 2026 registered direct offering and the pending warrant approval signal ongoing cash needs at a sub-$1 stock price. The authorized share doubling (Proposal 2) and equity plan increase (Proposal 3) provide management with tools for further dilutive financing. Monitor the December 1 vote outcome — if all proposals pass, the path is clear for additional capital raises that could pressure the stock. The activist 13D/A from Bios Equity Partners (May 2026) adds overhang; watch for any escalation ahead of or at the meeting.
Price Chart
Executive Summary
Lantern Pharma's 2026 definitive proxy statement schedules seven proposals for the December 1, 2026 annual meeting, including a doubling of authorized common stock to 50 million shares, a 250,000-share increase to the equity incentive plan, and stockholder approval of up to 3.67 million warrant shares from a September 2026 registered direct offering. The company reported a net loss of $17.1 million in 2025 (improved from $20.8 million in 2024) with total shareholder return declining 29% over two years. A prior SC 13D/A from Bios Equity Partners (filed May 2026) signals activist interest ahead of this meeting, though no proxy fight has materialized.
Key Facts
- Proposal to increase authorized common stock from 25 million to 50 million shares — a 2x increase.
- Proposal to add 250,000 shares to the equity incentive plan (total authorized pool becomes 2,114,680 shares).
- Proposal 4 seeks approval to issue up to 3,669,725 shares upon exercise of purchase warrants sold to an institutional investor at $1.09/share in a September 2026 registered direct offering.
- CEO Panna Sharma's total 2025 compensation was $763,750 (down 30% from $1,090,634 in 2024).
- Net loss improved to $(17,119,438) in 2025 from $(20,781,213) in 2024.
- Total shareholder return (TSR) declined 29% over the two-year period ended December 31, 2025.
- As of October 5, 2026, only 281,597 authorized shares remained unissued and unreserved.
- Board recommends 'FOR' all seven proposals; no shareholder proposals or contested director elections.
- Prior SC 13D/A from Bios Equity Partners, LP filed May 2026 — activist stake noted but no proxy fight initiated.
- Armistice Capital Master Fund Ltd. holds 9.99% of outstanding shares; Thomas A. Satterfield Jr. holds 6.53%; Biological Mimetics Inc. holds 5.65%.
Financial Impact
Full exercise of the 3,669,725 purchase warrants would add approximately $4.0 million in gross proceeds at $1.09/share, but would dilute existing shareholders by ~24.6% relative to the 14,935,576 shares outstanding as of the record date. The authorized share increase from 25M to 50M enables further future dilution without additional stockholder votes.
Risk Factors
- Massive authorized share increase (2x) enables substantial future dilution without further stockholder votes.
- Warrant exercise at $1.09/share adds 3.67M shares (24.6% dilution) if approved and exercised.
- Stock trades near $0.94 — well below the weighted-average option exercise price of $5.58, leaving most outstanding options deeply underwater.
- Activist presence (Bios Equity Partners 13D/A) could push for strategic alternatives or board changes.
- Net loss of $17.1M in 2025 with limited revenue visibility for a clinical-stage biotech.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEF 14A Filing (Primary) | 0001493152-26-047586 |
| Document: 0001493152-26-047586-index-headers.html | 0001493152-26-047586 |
| Document: 0001493152-26-047586-index.html | 0001493152-26-047586 |
| Document: 0001493152-26-047586.txt | 0001493152-26-047586 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | DEF 14A | $0.6564 | awaiting T+60 | — | $0.6240 (+4.94%) |
Oct 13, 2026 13d ago | SC 13G/A | $0.7107 | awaiting T+60 | — | $0.6240 (−12.20%) |
Oct 1, 2026 25d ago | 8-K | $0.8601 | awaiting T+60 | — | $0.6240 (+27.45%) |
Sep 30, 2026 26d ago | 8-K | $1.00 | awaiting T+60 | — | $0.6240 (+37.60%) |
Sep 30, 2026 26d ago | 424B5 | $1.01 | awaiting T+60 | — | $0.6240 (+38.22%) |
Sep 23, 2026 4w ago | 8-K | $1.21 | awaiting T+60 | — | $0.6240 (−48.43%) |
Sep 23, 2026 4w ago | 8-K | $1.39 | awaiting T+60 | — | $0.6240 (−55.11%) |
Aug 14, 2026 10w ago | 8-K | $2.65 | awaiting T+60 | — | $0.6240 (−76.45%) |
Jun 22, 2026 18w ago | EFFECT | $3.88 $1.70 | ▲ +56.19% | ▲ +57.93% | $0.6240 (+83.92%) |
May 15, 2026 23w ago | 8-K | $3.00 $2.66 | ▼ −11.33% | ▼ −16.18% | $0.6240 (−79.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers